替罗非班对NSTEMI患者PCI术后心肌再灌注影响的心肌声学造影评价

Myocardial Contrast Echocardiography Evaluation of Tirofiban for the Myocardial Reperfusion of NSTEMI Patients Underwent PCI Treatment

目的:探讨替罗非班对非ST段抬高型心肌梗死(NSTEMI)患者冠状动脉介入治疗(PCI)术后心肌再灌注的改善效果。方法:收取2012年4月至2015年4月在我院接受PCI治疗的NSTEMI患者78例作为研究对象,按照使用药物的不同将其分为观察组(n=38)及对照组(n=40)。对照组患者给予阿司匹林+氯吡格雷+肝素等常规治疗,观察组在此基础上加用替罗非班。使用心肌声学造影(MCE)评价两组患者心肌再灌注的情况。结果:PCI术前,两组患者A、β、Aβ、CK-MB及c Tn I比较差异均无统计学意义(P>0.05);治疗后,两组各指标均上升,且观察组β及Aβ显著高于对照组,CK-MB及c Tn I低于对照组(P<0.05)。观察组心脏不良事件发生率为2.63%,对照组为5.00%,两组安全性比较差异无统计学意义(P>0.05)。结论:替罗非班可显著改善NSTEMI患者PCI术后心肌再灌注,且安全性高。

Objective：To explore the improvement effect of tirofiban on the myocardial reperfusion of non-ST segmant elevated myocardial infarction（NSTEMI） patients underwent percutaneous coronary intervention（PCI） treatment.Methods：78 NSTEMI patients underwent PCI in our hospital from April 2012 to April 2015 were selected and divided into the observation group（n=38） and the control group（n=40） according to different drugs.Patients in the control group were given asprin,clopidogrel and heparin,while patients in the observation group were additionally given tirofiban.Then the myocardial contrast echocardiography（MCE） was taken to evluate the myocardial reperfusion.Results：No statistical difference was found in the levels of A,β,A β,CK-MB and c Tn I before PCI between 2groups.The levels of β,A β of observation group were obviously higher,CK-MB and c Tn I were obviously lower than those of the control group（P〈0.05）.The MACE rate of observation group was 2.63%,which was 5.00% in the control group,no significant difference was between two groups（P〉0.05）.Conclusion：Tirofiban could obviously improve the myocardial reperfusion of NSTEMI patients underwent PCI with high safety.